uniQure N.V.
QURE
Market Cap$792.21M
Close$
$-2.85
117.1% downside
Current Fair Value
117.1% downsideOvervalued by 117.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $792.21 Million |
|---|---|
| Enterprise Value | $646.45 Million |
| Dividend Yield | $0 (0%) |
| Earnings per Share | $-4.92 |
| Beta | 0.1 |
| Outstanding Shares | 53,110,580 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -3.53 |
|---|---|
| PEG | 10.54 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 32 |
| Enterprise Value to EBIT | -3.51 |
| Enterprise Value to Net Income | -3 |
| Total Debt to Enterprise | 0.11 |
| Debt to Equity | 2.12 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About uniQure N.V.
uniQure is delivering on the promise of gene therapy - single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary gene therapies to tr...